Financial updates
Pharming Group Report on Preliminary Financial Results for 2017
Pharming Group N.V. presents its preliminary (unaudited) financial report for the full year ended 31 December 2017.
“The remarkable growth reported in 2017 was a direct result of our strategic decisions to reacquire the commercial rights to RUCONEST® in North America and implement direct marketing in the major Western European markets.”
- Sijmen de Vries - CEO